Marksans Pharma arm secures UK health regulator nod for epilepsy treatment drug

Marksans Pharma Ltd shares gained over 2% in morning trade on Thursday, May 15, after the company announced its UK subsidiary Relonchem Ltd had secured marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (UKMHRA) for its Gabapentin oral solution, 50 mg/ml. It is used for the treatment of nerve pain and epilepsy.

The clearance will help Marksans Pharma to expand its portfolio of central nervous system (CNS) products in the UK and broader European markets, the company said.

Gabapentin is widely prescribed for the treatment of nerve pain and epilepsy, and the new oral solution format is particularly useful for patients who have difficulty swallowing tablets or capsules.

“This authorisation further strengthens our CNS product offering in the UK and demonstrates our focus on providing high-quality, patient-centric solutions,” Harshavardhan Panigrahi, Company Secretary of Marksans Pharma, said.

In March, the pharma company received approval for its manufacturing facility in Verna, Goa, from Australia’s Therapeutic Goods Administration (TGA).

The Australian regulator cleared the Goa-based facility to produce solid dosage forms—such as tablets and hard capsules—for the Australian market.

In the same month, Relonchem also received Marketing Authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency for Baclofen 10 mg tablets. The drug helps in relaxing certain muscles in the body, alleviating spasms, cramping, and tightness caused by multiple sclerosis or spinal injuries.

Shares of Marksans Pharma gained nearly 2.3% to hit an intraday high of ₹243.65 apiece on Thursday, May 15. The stock was up 0.98% at ₹240.61 apiece at 2.50 pm.

Also Read: South Indian Bank Q4 | Net profit up 19%, asset quality improves